Orient Technologies (NSE: ORIENTTECH) Q3 FY26 results: Why short-term margin pain may be the price of securing long-cycle government and services revenue
Read More 5 minute read Pharma Industry News MetaVia unveils breakthrough Phase 2a data showing vanoglipel improves liver markers and glucose control in MASH patients Find out how MetaVia’s vanoglipel improved liver enzymes and glucose control in its Phase 2a MASH trial — see why investors are taking notice today. bySoujanya RaviNovember 7, 2025